as 06-20-2025 4:00pm EST
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.
Founded: | 1997 | Country: | United States |
Employees: | N/A | City: | ALISO VIEJO |
Market Cap: | 631.1M | IPO Year: | 2021 |
Target Price: | $39.30 | AVG Volume (30 days): | 661.3K |
Analyst Decision: | Buy | Number of Analysts: | 10 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.67 | EPS Growth: | N/A |
52 Week Low/High: | $12.53 - $60.81 | Next Earning Date: | 08-04-2025 |
Revenue: | $148,310,000 | Revenue Growth: | 46.70% |
Revenue Growth (this year): | 22.16% | Revenue Growth (next year): | 20.91% |
RXST Breaking Stock News: Dive into RXST Ticker-Specific Updates for Smart Investing
Simply Wall St.
a day ago
Zacks
3 days ago
TipRanks
21 days ago
Zacks
a month ago
GlobeNewswire
a month ago
Insider Monkey
a month ago
MT Newswires
a month ago
MT Newswires
a month ago
The information presented on this page, "RXST RxSight Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.